![PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)](https://i1.rgstatic.net/publication/343051230_Overall_survival_results_from_the_randomized_phase_2_study_of_palbociclib_in_combination_with_letrozole_versus_letrozole_alone_for_first-line_treatment_of_ERHER2-_advanced_breast_cancer_PALOMA-1_TRIO-/links/5f17d599299bf1720d58dd64/largepreview.png)
PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
1 de 7 PROSPECTO: INFORMACIÓN PARA EL PACIENTE Letrozol ratiopharm 2,5 mg comprimidos recubiertos con película EFG Letrozol Le
![Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial | Journal of Clinical Oncology Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2019/jco.2019.37.issue-3/jco.18.01624/20190107/images/large/jco.18.01624t3.jpeg)
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial | Journal of Clinical Oncology
![PDF) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study PDF) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study](https://i1.rgstatic.net/publication/333940583_Influence_of_patient_and_tumor_characteristics_on_therapy_persistence_with_letrozole_in_postmenopausal_women_with_advanced_breast_cancer_results_of_the_prospective_observational_EvAluate-TM_study/links/5d0d895192851cf44040e2b8/largepreview.png)